Long-term data demonstrate that robust reductions and normalization in key biomarkers from baseline were maintained over time with continued ...

Denali Therapeutics (DNLI) announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome in the 24-week ...

After winning a breakthrough therapy designation for its Hunter syndrome enzyme replacement therapy, Denali Therapeutics is ...

Research analysts at Zacks Research decreased their FY2024 EPS estimates for shares of Denali Therapeutics in a research report issued on Tuesday, January 28th. Zacks Research analyst A. Chakraborty ...

Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Denali Therapeutics Inc. (DNLI) stock price is 23.30 and Denali Therapeutics Inc. (DNLI) 10-day simple moving average is 23.08. Denali Therapeutics Inc. (DNLI) stock price is 23.30 and Denali ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2 Planned workforce reduction of approximately 40% of employees Corporate even ...